Abstract
Background Extracorporeal cardiopulmonary resuscitation (eCPR) improves outcomes after out of hospital cardiac arrest (OHCA). However, bleeding and thrombosis are common complications. The post cardiac arrest syndrome including trauma and altered hemostasis creates challenges when balancing the risk of bleeding versus thrombosis. We aimed to describe the incidence and predictors of bleeding and thrombosis and their association with in-hospital mortality.
Methods Consecutive patients presenting with refractory VT/VF OHCA between December 2015 and March 2022 who met criteria for eCPR initiation at our center were included. Patients were anticoagulated with unfractionated heparin while on ECMO. Major bleeding was defined by the extracorporeal life support organization’s (ELSO) criteria as clinically significant bleed associated with transfusion of ≥2 units of red blood cells in 24h or bleeding in a critical area. Thrombosis was defined by clinical signs and symptoms and or imaging evidence of thrombi. Adjusted analyses were done to seek out risk factors for bleeding and thrombosis and evaluate their association with mortality.
Results Major bleeding occurred in 135/200 patients (67.5%) with traumatic bleeding from CPR in 73/200 (36.5%). Baseline demographics and arrest characteristics were similar between groups. In multivariable regression analysis only fibrinogen was independently associated with bleeding (aHR 0.98 per every 10mg/dl rise, 95% CI: 0.96-0.99). Patients who died had a higher rate of bleeds per day (0.21 vs 0.03,p<0.001) though bleeding was not significantly associated with in-hospital death (aHR 0.81, 95% CI: 0.55-1.19). A thrombotic event occurred in 23.5% (47/200). Venous thromboembolism (VTE) occurred in 11% (22/200) and arterial thrombi in 15.5% (31/200). Clinical characteristics were comparable between groups. In adjusted analyses, antithrombin III level on admission (aHR 0.97, 95% CI: 0.94-0.99) and use of dual anti-platelet therapy (DAPT) (aHR 0.31, 95% CI: 0.11-0.86) were associated with the incidence of thrombosis. Thrombosis was not associated with in-hospital death (aHR 0.65, 95% CI: 0.42- 1.03).
Conclusion Bleeding is a frequent complication of eCPR that is associated with decreased fibrinogen levels on admission. Thrombosis is less common occurring in 24% of the cohort. Neither bleeding nor thrombosis was significantly associated with in-hospital mortality.
What is new?
In this large single center study with a protocolized approach to anticoagulation for patients with VT/VF OHCA bleeding as defined by ELSO major bleeding was common occurring in 68% of the cohort while thrombosis was less frequent occurring in 24% with the more than half of the events being arterial thrombi.
Bleeding events are multifactorial including trauma from prolonged CPR, access site bleeding, and mucosal bleeding.
Neither bleeding nor thrombosis is associated with overall in-hospital mortality.
What are the Clinical implications?
The high incidence of bleeding and low incidence of thrombosis with the current approach to anticoagulation which often involves antithrombotic therapy reinforces the need for a better method to risk stratify patients to better tailor anticoagulation strategies.
The lack of association of bleeding and thrombotic events with mortality support a less aggressive anticoagulation strategy to minimize bleeding.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed and approved by the Institutional Review Board (IRB) at the UMN (IRB #1703M11301).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is available upon request
